L-Arginine, glycyl-L-histidyl-L-arginyl-L-prolyl-L-leucyl-L-α-aspartyl-L-lysyl-L-lysyl-L-arginyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-prolyl-L-seryl-L-leucyl-L-arginyl-L-prolyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-isoleucyl-L-serylglycylglycylglycyl-L-tyrosyl- manufacturers
- FX-06
-
-
2026-07-15
- CAS:88650-17-3
- Purity:
- Supply Ability: 10g
|
| | L-Arginine, glycyl-L-histidyl-L-arginyl-L-prolyl-L-leucyl-L-α-aspartyl-L-lysyl-L-lysyl-L-arginyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-prolyl-L-seryl-L-leucyl-L-arginyl-L-prolyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-isoleucyl-L-serylglycylglycylglycyl-L-tyrosyl- Basic information |
| | L-Arginine, glycyl-L-histidyl-L-arginyl-L-prolyl-L-leucyl-L-α-aspartyl-L-lysyl-L-lysyl-L-arginyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-prolyl-L-seryl-L-leucyl-L-arginyl-L-prolyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-isoleucyl-L-serylglycylglycylglycyl-L-tyrosyl- Chemical Properties |
| density | 1.54±0.1 g/cm3(Predicted) | | form | Solid | | color | White to off-white |
| | L-Arginine, glycyl-L-histidyl-L-arginyl-L-prolyl-L-leucyl-L-α-aspartyl-L-lysyl-L-lysyl-L-arginyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-prolyl-L-seryl-L-leucyl-L-arginyl-L-prolyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-isoleucyl-L-serylglycylglycylglycyl-L-tyrosyl- Usage And Synthesis |
| Uses | FX-06 (Fibrin-derived peptide Bβ15-42) is a fibrin Bbeta chain-derived peptide. FX-06 binds to VE-cadherin and inhibits leukocyte transmigration and initiates VE-cadherin-mediated signaling. FX-06 can be used in the research of ischemia/reperfusion injury, Dengue shock syndrome (DSS)[1][2][4]. | | in vivo | FX06 (2.4 mg/kg, i.v. bolus) shows significantly improved pulmonary and circulatory function in a pig model of hemorrhagic shock and reperfusion[3].
FX06 (2.4 mg/kg, i.p., twice daily) improves survival and reduces capillary leak in mice with Dengue-induced shock[4].
FX06 (3.6 mg/kg, i.v.) protects mice from Ischemia/reperfusion (I/R)-induced kidney injury by aiding in epithelial cell proliferation and tissue repair[5].
| Animal Model: | Pig model of hemorrhagic shock and reperfusion [3] | | Dosage: | 2.4 mg/kg | | Administration: | Intravenous injection (i.v.) bolus | | Result: | Reduced raccumulation of myeloperoxidase-pos. cells (mainly neutrophils) in myocardium, liver, and small intestine, and reduced interleukin-6 plasma levels. |
| Animal Model: | Mice with Dengue-induced shock[4] | | Dosage: | 2.4 mg/kg | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Significantly improved survival rates, reduced capillary leak within lungs and the intestine, and reduced hemoconcentration and fibrinogen consumption. |
| | References | [1] Ahrens I, et al. FX-06, a fibrin-derived Bbeta15-42 peptide for the potential treatment of reperfusion injury following myocardial infarction. Curr Opin Investig Drugs. 2009 Sep;10(9):997-1003. PMID:19705343
[2] Zou F, et al. Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening. Bioorg Med Chem Lett. 2018 Feb 1;28(3):388-393. DOI:10.1016/j.bmcl.2017.12.030
[3] Roesner JP, et al. Bbeta15-42 (FX06) reduces pulmonary, myocardial, liver, and small intestine damage in a pig model of hemorrhagic shock and reperfusion. Crit Care Med. 2009 Feb;37(2):598-605. DOI:10.1097/CCM.0b013e3181959a12
[4] Grger M, et al. Peptide Bbeta(15-42) preserves endothelial barrier function in shock. PLoS One. 2009;4(4):e5391. DOI:10.1371/journal.pone.0005391
[5] Aparna Krishnamoorthy, et al. Fibrinogen β–derived Bβ15-42 peptide protects against kidney ischemia/ reperfusion injury. Blood (2011) 118 (7): 1934–1942. |
| | L-Arginine, glycyl-L-histidyl-L-arginyl-L-prolyl-L-leucyl-L-α-aspartyl-L-lysyl-L-lysyl-L-arginyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-prolyl-L-seryl-L-leucyl-L-arginyl-L-prolyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-isoleucyl-L-serylglycylglycylglycyl-L-tyrosyl- Preparation Products And Raw materials |
|